Visa to buy Visa Europe in deal worth as much as $23 billion
(Reuters) – Visa Inc said on Monday it would buy former subsidiary Visa Europe Ltd for up to $23.3 billion in a deal that will give the world’s largest payments network a chance to cut costs over the long term and raise fees in the second-biggest card …
Citron publishes no new allegations against Valeant, shares rise
NEW YORK (Reuters) – Influential short-selling firm Citron Research did not publish new allegations against Valeant Pharmaceuticals International Inc on Monday as many investors had anticipated, giving the beleaguered shares of the Canadian drugmaker a…
U.S. on track to grow 1.9 percent in fourth quarter: Atlanta Fed
NEW YORK (Reuters) – The U.S. economy is on track to grow 1.9 percent in the fourth quarter with expected weaker consumer spending and equipment investment growth following a private report on U.S. manufacturing in October, the Atlanta Federal Reserve’…
Quebec sees no trade dispute risk around Bombardier investment
TORONTO (Reuters) – Quebec is sure that its $1 billion lifeline for Bombardier Inc will not result in any trade disputes triggered by concerns from the train and plane maker’s rivals, the Canadian province’s finance minister said on Monday.
Goldman Sachs says Valeant has long road ahead, cuts rating
(Reuters) – Goldman Sachs on Monday downgraded Valeant Pharmaceuticals International Inc’s stock, nearly two weeks after an influential short seller accused the Canadian drug maker of cooking its books.
Shire to buy Dyax for $5.9 billion, still wants Baxalta
LONDON (Reuters) – Shire Plc has agreed to buy U.S. rare disease specialist Dyax Corp for about $5.9 billion – and potentially up to $6.5 billion – while still pursuing a five times larger unsolicited bid for Baxalta Inc .
Exclusive: Guggenheim, JPMorgan clinch key roles in Pfizer-Allergan talks
NEW YORK/LONDON (Reuters) – Investment banks Guggenheim Partners LLC and JPMorgan Chase & Co have secured key roles in Pfizer Inc’s merger negotiations with Allergan Plc , according to people familiar with the matter, in what would be the biggest ever deal in the pharmaceutical sector.
George Soros’s firm pulls $500 million from Bill Gross of Janus
NEW YORK (Reuters) – Bill Gross just got a huge vote of “no confidence” from billionaire investor George Soros.
U.S. manufacturing weakness persists; worst may be over
WASHINGTON (Reuters) – U.S. manufacturing activity in October hit a 2-1/2-year low, but a rise in new orders offered hope for a sector buffeted by a strong dollar and relentless spending cuts by energy companies.
Cartier CEO off work ill, unclear when will return: sources
PARIS (Reuters) – Stanislas de Quercize, chief executive of jeweller and watch-maker Cartier, has been off for several weeks due to health problems, sources close to the matter said.
